Prophylaxis of glucocorticoid-induced osteoporosis

Abstract

Glucocorticoid (GC) is widely used to treat a variety of inflammatory and allergic diseases and about one million people in Japan are known to take oral GC. GC causes a number of significant side effects and among them osteoporosis and degenerative bone fracture are major complications of GC therapy. However, few physicians are aware of the increased risk of fracture caused by GC, and there is inadequate information concerning the effectiveness of prevention and treatment of GC-induced osteoporosis. Recent multiple evidence strongly indicates that bisphosphonate is effective for treatment and prophylaxis of GC-induced osteoporosis by improving both quantity and quality of bones, which results in reduction of the proportion of fractures.